KRMCF yields 454.55% · PFE yields 6.13%● Live data
📍 KRMCF pulled ahead of the other in Year 1
Combined, KRMCF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KRMCF + PFE for your $10,000?
KRM22 Plc, together with its subsidiaries, develops and sells risk management software to the financial services industry in the United Kingdom, Europe, the United States, and internationally. The company offers Risk Cockpit, which shows enterprise risk profile in real time; Regulatory Navigator that brings out-the-box regulatory functionality covering market abuse, SM&CR, and financial crime; and Market Surveillance that offers analytics and contextual market surveillance tools to help capital markets firms identify and manage the potential risks of market abuse, fraud, and operational breaches. It also provides Individual Accountability Regime, which allows financial institutions to manage accountability throughout the firm; Digital Client Onboarding that provides capital market firms with the tools to make client onboarding; and Regulatory Reporting that enables capital market firms to comply with its regulatory reporting obligations across multiple jurisdictions. In addition, the company offers Enhanced Due Diligence, which enables firms to understand online reputational risks and evidence compliance; Regulatory training that helps regulated firms address their mandatory training requirements; Post-Trade Risk Stress, which scales the type and amount of risk calculations performed against various limits and risk slides; and Post-Trade Risk VaR that provides the unique view of multiple VaR calculations across the whole portfolio in a single place. Further, it provides At-Trade Risk, which offers P&L and exchange margin for clearing houses and members, traders, brokers, and other financial institutions that make decisions based on the management of risk; and Pre-Trade Risk, which helps combat time consuming and error prone processes by maintaining pre-trade limits in one centralized application. The company was founded in 2017 and is headquartered in London, the United Kingdom.
Full KRMCF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.